Fuzeon Viral Decay Pilot Study
A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1L6
- Maple Leaf Medical Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must be HIV infected
- Patient must be > 18 years old
- Patient must be taking standard combination antiretroviral therapy with 2-3 NRTIs and 1-2 PIs or a NNRTIs for at least five years
- Patient must have a viral load < 50 copies/mL (using the standard available methods of detection) during the entire time on standard combination antiretroviral therapy except for initial fall of viral load
- Patient must have a CD4 count above 400 cells/mm3 in last 3 months
- Female patient must agree to use two methods of birth control or abstinence during the period of the study
- Patient has to have signed full informed consent
Exclusion Criteria:
- Patient who would have difficulty participating in a trial due to non-adherence or substance abuse
- Patient who have taken mono or dual antiretroviral therapy
- Patient who have had a viral load > 50 copies/mL on any antiretroviral regimen
Patient with any of the following abnormal laboratory test results in screening:
- Hemaglobin < 100 g/L
- Neutrophil count < 750 cells/uL
- Platelet count < 50,000 cells/L
- AST or ALT > 5X the upper limit of normal
- Creatinine > 250 umol/L
- Patient with a malignancy
- Patient with other significant underlying disease (non-HIV) that might impinge upon disease progression or death
- Patient with an active AIDS-defining illnesses in the past six months
- Patients who are pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Did not receive enfuvirtide
patients were randomized to either receive enfuviratide or not receive it
|
1ml BID
|
|
ACTIVE_COMPARATOR: enfuvirtide
enfuvirtide 1ml BID
|
1ml BID
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of proviral HIV-1 DNA in both purified resting and activated CD4 T cells from baseline to month 6.
Time Frame: 6 months
|
The change of proviral HIV-1 DNA in both purified resting and activated CD4 T cells from baseline to month 6.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine the change of proviral HIV-1 DNA from baseline to month 3
Time Frame: 3 months
|
To determine the change of proviral HIV-1 DNA from baseline to month 3
|
3 months
|
|
To determine the change of proviral HIV-1 DNA from months 6 to 9 after the enfurvitide has been stopped for 3 months in the treatment arm
Time Frame: 9 months
|
To determine the change of proviral HIV-1 DNA from months 6 to 9 after the enfurvitide has been stopped for 3 months in the treatment arm
|
9 months
|
|
To quantify plasma HIV (limit of detection 2 copies/ml of plasma)
Time Frame: 9 months
|
To quantify plasma HIV (limit of detection 2 copies/ml of plasma)
|
9 months
|
|
To quantify cell associated HIV RNA (unspliced and multiply spliced) in resting and activated CD4+ T cells
Time Frame: 9 months
|
To quantify cell associated HIV RNA (unspliced and multiply spliced) in resting and activated CD4+ T cells
|
9 months
|
|
To determine the decay characteristics of HIV in resting CD4+ T cells by quantitative co-culture assays
Time Frame: 9 months
|
To determine the decay characteristics of HIV in resting CD4+ T cells by quantitative co-culture assays
|
9 months
|
|
To determine the half-life of HIV in resting CD4+ T cells
Time Frame: 9months
|
To determine the half-life of HIV in resting CD4+ T cells
|
9months
|
|
To carry out phylogenetic analysis of HIV in the plasma, resting, and activated CD4+ T cell compartments
Time Frame: 9 months
|
To carry out phylogenetic analysis of HIV in the plasma, resting, and activated CD4+ T cell
|
9 months
|
|
To quantify the amount of HIV in gastrointestinal-associated lymphoid tissue (GALT) by quantitative co-culture assays (as part of a sub-study - see GALT sub-study)
Time Frame: 9 months
|
To quantify the amount of HIV in gastrointestinal-associated lymphoid tissue (GALT) by quantitative co-culture assays (as part of a sub-study - see GALT sub-study)
|
9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Colin Kovacs, MD, University of Toronto
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Roche-FVD-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.